A comprehensive view of Weight Management Products. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Consumer Wellness Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

Morgan Stanley names Wendy's, Jack in the Box, Wingstop as fast-food chains to face pressure from rise in GLP-1 drugs like Ozempic, as people spend less at restaurants; healthier fast-casual restaurants poised to handle looming shift in consumer spending
Published: April 22, 2024 by Quartz
High demand for injectable weight-loss drugs has led to supply issues, with most varieties listed in short supply by the FDA; Eli Lilly reports shortages of its Zepbound and Mounjaro could last until 2025
Published: April 19, 2024 by CBS - 12 WJTV (Jackson, MS)
GlobalData predicts GLP-1 drugs will redefine big pharma sales; Eli Lilly's diabetes drug, Mounjaro, is forecasted to generate US$34.0B by 2029, surpassing the entire 2023 portfolio of Lilly, with the Alzheimer's drug donanemab adding another US$5.0B
Published: April 17, 2024 by FiercePharma
Eli Lilly proposes revisions to FDA guidance addressing obesity, identifying obesity as a chronic disease and requesting updated practices for clinical trials to better address the growing public health crisis
Published: April 12, 2024 by Targeted News Service
Commentary: Excessive costs on GLP-1 medications from Eli Lilly and Novo Nordisk have led to their inaccessibility in low-/middle-income nations; report finds if branded companies were to partner with generics makers, prices could be less than US$1/month
Published: April 08, 2024 by Indian Pharma Industry: Policies

Ask us about our Consumer Wellness market view

Trending Chart

Interactive chart with headline count